Publication: Cyp2d6 predicts plasma donepezil concentrations in a cohort of thai patients with mild to moderate dementia
Issued Date
2020-01-01
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-85095813329
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.13, (2020), 543-551
Suggested Citation
Monpat Chamnanphon, Sorawit Wainipitapong, Teeravut Wiwattarangkul, Phenphichcha Chuchuen, Kunathip Nissaipan, Weeraya Phaisal, Sookjaroen Tangwongchai, Chonlaphat Sukasem, Supeecha Wittayalertpanya, Andrea Gaedigk, Daruj Aniwattanapong, Pajaree Chariyavilaskul Cyp2d6 predicts plasma donepezil concentrations in a cohort of thai patients with mild to moderate dementia. Pharmacogenomics and Personalized Medicine. Vol.13, (2020), 543-551. doi:10.2147/PGPM.S276230 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59895
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cyp2d6 predicts plasma donepezil concentrations in a cohort of thai patients with mild to moderate dementia
Abstract
© 2020 Chamnanphon et al. Tterms.php and incorporate the. Purpose: Donepezil, a drug frequently used to treat dementia, is mainly metabolized by cytochrome P450 2D6 (CYP2D6). This study investigated the relationships between CYP2D6 genotype and activity scores as well as predicted phenotype of plasma donepezil concentrations in 86 Thai dementia participants. Materials and Methods: CYP2D6 was genotyped using bead-chip technology (Luminex xTAG® v.3). Steady-state trough plasma donepezil concentrations were measured using high-performance liquid chromatography. Results: Sixteen genotypes were found but the most frequent genotypes detected among our participants were CYP2D6*10/*10 (27.9%) and *1/*10 (26.7%). One-third of the participants had an activity score of 1.25 which predicted that they were normal metabolizers. The overall median (interquartile range) of plasma donepezil concentration was 51.20 (32.59–87.24) ng/mL. Normal metabolizers (NMs) had lower plasma donepezil concentrations compared to intermedi-ate metabolizers (IMs) (41.15 (28.44–67.65) ng/mL vs 61.95 (35.25–97.00) ng/mL). Multivariate analysis showed that CYP2D6 activity score (r2 = 0.50) and the predicted phenotype (independent of dose) could predict the plasma donepezil concentration (r2 = 0.49). Conclusion: Plasma donepezil concentration in NMs was lower compared to IMs. Additional studies with larger sample size and use of next-generation sequencing as well as its outcomes are warranted to confirm the benefit of using pharmacogenetic-guided treatment for donepezil.